# Arcutis Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arcutis-biotherapeutics

- Industry: Biotechnology
- Headquarters: Westlake Village, US
- Website: www.arcutis.com
- Total disclosed funding: $166M
- Latest round: Series C (Oct 8, 2019)
- Investors on record: 10

## About

Based in California, US and founded in 2016, Arcutis Biotherapeutics, Inc. develops and commercializes novel immuno-dermatology drugs intended for patients with skin conditions. The company was co-founded by Bhaskar Chaudhuri and David W. Osborne. In October 2023, Arcutis Biotherapeutics, Inc. raised USD 100 million in a private placement, selling 32.5 million shares at USD 3.23 per share on the Nasdaq Global Select Market under the ticker symbol "ARQT". Arcutis Biotherapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 15 million shares of common stock as part of the listing. 

The company works with pharmaceutical companies, by offering immuno-dermatology drugs for patients with skin conditions. Arcutis Biotherapeutics, Inc. develops novel treatments for skin conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, hand eczema, vitiligo, and alopecia areata. Products include ARQ-151 - for plaque and atopic dermatitis, ARQ-154 – for seborrheic dermatitis and scalp psoriasis, ARQ-252 – for hand eczema and vitiligo, and ARQ-255 – for alopecia areata. The company will show the different drugs development to pharmaceutical companies, then the latter will negotiate, purchase, and manufacture the drugs. The products can then be purchased by the public.

Arcutis Biotherapeutics, Inc.’s revenue will be generated by selling the developed treatment, intended for patients with skin conditions, to pharmaceutical companies.

The company’s future growth plan is to use the funding for product research and development.

## Funding rounds

- Series C, Oct 8, 2019, $95M — Frazier Healthcare Partners, OrbiMed Advisors, Bain Capital, HBM Partners, Vivo Capital, Omega Funds, Goldman Sachs Asset Management, BlackRock, RA Capital Management, Pivotal Life Sciences
- Series B, Sep 1, 2018, $58M — Frazier Healthcare Partners, OrbiMed Advisors, Bain Capital
- Series A, Apr 1, 2017, $14M — Frazier Healthcare Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series C